Brief: Ocuphire Pharma Announces Last Patient Completes Final Visit In Zeta-1 Phase 2B 24-Week Trial Of Oral Apx3330 In Diabetic Retinopathy
08/09/2022 13:04
Sept 8 (Reuters) - Ocuphire Pharma Inc OCUP.O :
* OCUPHIRE PHARMA ANNOUNCES LAST PATIENT COMPLETES FINAL
VISIT IN
ZETA-1 PHASE 2B 24-WEEK TRIAL OF ORAL APX3330 IN DIABETIC
RETINOPATHY
* OCUPHIRE PHARMA INC - TOP-LINE RESULTS ARE EXPECTED IN 4Q
2022
* OCUPHIRE PHARMA- INTERIM MASKED SAFETY RESULTS SEEN
DEMONSTRATE
FAVORABLE SAFETY AND TOLERABILITY PROFILE, CONSISTENT WITH 11
PRIOR TRIALS OF APX3330
Source text for Eikon: ID:nGNX5Ygc3M
Further company coverage: OCUP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Opus Genetics
See all newsUS RESEARCH ROUNDUP-Affiliated Managers Group, Goldman Sachs, Vaxcyte
Health Rounds: Experimental eye drops ease night vision problems for drivers
U.S. STOCKS ON THE MOVE-Apple, Omnicom, Jersey Mike's Subs
U.S. STOCKS ON THE MOVE-Airbnb, Lyft, Korn Ferry
Opus Genetics hits 5-year high on positive early- to mid-stage eye disease gene therapy data